Albireo Financial Statements From 2010 to 2023

ALBO Stock  USD 44.61  0.02  0.0449%   
Albireo Pharma financial statements provide useful quarterly and yearly information to potential Albireo Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Albireo Pharma financial statements helps investors assess Albireo Pharma's valuation, profitability, and current liquidity needs.
We have found ninety-three available fundamental signals for Albireo Pharma, which can be analyzed and compared to other ratios and to its rivals. Make sure you validate Albireo Pharma's prevailing fundamentals against the trend between 2010 and 2023 to make sure the company can sustain itself down the road.
Albireo Pharma Working Capital is very stable at the moment as compared to the past year. Albireo Pharma reported last year Working Capital of 257.12 Million.
  
Check Albireo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Albireo main balance sheet or income statement drivers, such as Direct Expenses of 1.2 M, Cost of Revenue of 1.2 M or Gross Profit of 48.7 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0502, PPandE Turnover of 67.56 or Receivables Turnover of 6.79. Albireo financial statements analysis is a perfect complement when working with Albireo Pharma Valuation or Volatility modules. It can also supplement Albireo Pharma's financial leverage analysis and stock options assessment as well as various Albireo Pharma Technical models . Please continue to the analysis of Albireo Pharma Correlation against competitors.

Albireo Pharma Revenues

39.4 Million

Albireo Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Tax Liabilities74.7 K67.5 K78.3 K
Down
Slightly volatile
Tax Assets5.5 K5.4 K10 K
Down
Slightly volatile
Trade and Non Trade Receivables4.1 M3.8 M1.9 M
Up
Slightly volatile
Property Plant and Equipment Net602.7 K601.2 K622.7 K
Down
Slightly volatile
Trade and Non Trade Payables8.1 M7.5 M3.1 M
Up
Slightly volatile
Liabilities Non Current100.6 M93.3 M34.8 M
Up
Slightly volatile
Current Liabilities44 M40.8 M15.9 M
Up
Slightly volatile
Total Liabilities122.8 M113.8 M46.9 M
Up
Slightly volatile
Inventory173.6 K174.6 K191.2 K
Down
Slightly volatile
Goodwill and Intangible Assets16.5 M19.8 M12.7 M
Up
Slightly volatile
Shareholders Equity USD217.9 M201.9 M85.8 M
Up
Slightly volatile
Shareholders Equity170.5 M158 M84.3 M
Up
Slightly volatile
Total Debt USD10.4 M11.5 M8.4 M
Up
Slightly volatile
Debt Non Current10.8 M11.5 M7.8 M
Up
Slightly volatile
Debt Current3.5 M3.5 M2.9 M
Up
Slightly volatile
Total Debt10.4 M11.5 M8.4 M
Up
Slightly volatile
Cash and Equivalents USD307.8 M285.3 M116 M
Up
Slightly volatile
Cash and Equivalents240.9 M223.3 M109.9 M
Up
Slightly volatile
Assets Non Current41.1 M38.1 M15.7 M
Up
Slightly volatile
Current Assets261.1 M242 M116.7 M
Up
Slightly volatile
Total Assets293.3 M271.8 M131.2 M
Up
Slightly volatile
Accumulated Other Comprehensive Income916.7 K994.5 K890.7 K
Down
Very volatile
Accounts Payable6.3 M5.9 M2.8 M
Up
Slightly volatile
Receivables3.2 M2.9 M1.5 M
Up
Slightly volatile
Inventories173.6 K174.6 K191.2 K
Down
Slightly volatile

Albireo Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Income Tax Expense23.6 K23 K44.6 K
Down
Very volatile
Weighted Average Shares Diluted18.7 M17.3 M7.8 M
Up
Slightly volatile
Weighted Average Shares18.7 M17.3 M7.8 M
Up
Slightly volatile
Selling General and Administrative Expense86.3 M80 M27.7 M
Up
Slightly volatile
Research and Development Expense102.4 M94.9 M37.2 M
Up
Slightly volatile
Revenues USD50.3 M46.7 M15 M
Up
Slightly volatile
Revenues39.4 M36.5 M16.2 M
Up
Slightly volatile
Operating Expenses201.9 M187.1 M66.3 M
Up
Slightly volatile
Interest Expense17.3 M16 M5.7 M
Up
Slightly volatile
Gross Profit48.7 M45.1 M14.7 M
Up
Slightly volatile
Cost of Revenue1.2 M1.2 M1.3 M
Down
Slightly volatile
Direct Expenses1.2 M1.2 M1.3 M
Down
Slightly volatile

Albireo Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Share Based Compensation19.8 M18.3 MM
Up
Slightly volatile
Effect of Exchange Rate Changes on Cash (1.2 M)(1.2 M)(642.6 K)
Down
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals5.4 M5.4 M5.9 M
Down
Slightly volatile
Net Cash Flow from Investing99.9 M92.6 M22.8 M
Up
Slightly volatile
Net Cash Flow from Financing2.5 M2.5 M37.7 M
Up
Pretty Stable
Issuance Repayment of Debt Securities 11.8 M10.9 M5.1 M
Up
Slightly volatile
Issuance Purchase of Equity Shares3.3 M3.2 M30.4 M
Up
Pretty Stable
Net Cash Flow Business Acquisitions and Disposals99.9 M118.9 M65.3 M
Up
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(3.7 M)(3.6 M)16.5 M
Up
Pretty Stable
Depreciation Amortization and Accretion267.9 K246.6 K295.6 K
Down
Slightly volatile
Capital Expenditure(429.5 K)(418.5 K)136.3 K
Down
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Tangible Assets Book Value per Share13.6913.3439.8015
Down
Slightly volatile
Sales per Share2.592.435.2507
Down
Slightly volatile
Return on Invested Capital18.0420.7416.5076
Down
Slightly volatile
Price to Sales Ratio10.199.9314.3 K
Up
Very volatile
Price to Book Value2.692.941.778
Up
Slightly volatile
Gross Margin86.4886.9995.241
Down
Slightly volatile
Enterprise Value over EBITDA(9.15)(8.91)(3.0997)
Down
Slightly volatile
Enterprise Value over EBIT(9.24)(9.0)(3.2312)
Down
Slightly volatile
Debt to Equity Ratio0.07170.06550.0706
Down
Slightly volatile
Current Ratio10.166.8210.9037
Down
Slightly volatile
Book Value per Share8.448.2225.0076
Down
Slightly volatile
Asset Turnover0.140.160.1695
Down
Slightly volatile
Total Assets Per Share18.4718.033.7201
Down
Slightly volatile
Receivables Turnover6.796.32.9358
Up
Slightly volatile
PPandE Turnover67.5681.4461.1964
Down
Pretty Stable
Cash and Equivalents Turnover0.170.190.2135
Down
Slightly volatile
Accounts Payable Turnover7.197.9110.293
Down
Slightly volatile
Accrued Expenses Turnover1.591.71.8362
Down
Slightly volatile
Long Term Debt to Equity0.05020.05130.053
Down
Pretty Stable
Quick Ratio8.056.188.0393
Down
Pretty Stable
Net Current Assets as percentage of Total Assets91.0985.1280.6443
Down
Very volatile
Revenue to Assets0.130.150.1551
Down
Slightly volatile

Albireo Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Working Capital277.4 M257.1 M104.9 M
Up
Slightly volatile
Tangible Asset Value353.4 M327.5 M128.6 M
Up
Slightly volatile
Market Capitalization557.1 M516.3 M242.7 M
Up
Slightly volatile
Invested Capital Average(846.8 K)(784.8 K)(1.5 M)
Down
Very volatile
Invested Capital1.3 M1.2 M(1.5 M)
Up
Very volatile
Enterprise Value181.2 M225.8 M112.4 M
Up
Slightly volatile
Average Equity191.9 M177.9 M83.6 M
Up
Slightly volatile
Average Assets331.2 M307 M130 M
Up
Slightly volatile
Revenue Per Employee360.5 K359 K552 K
Down
Slightly volatile

Albireo Fundamental Market Drivers

Cash And Short Term Investments248.1 M

Albireo Upcoming Events

Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Albireo Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Albireo Pharma income statement, its balance sheet, and the statement of cash flows. Albireo Pharma investors use historical funamental indicators, such as Albireo Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Albireo Pharma investors may use each financial statement separately, they are all related. The changes in Albireo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Albireo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Albireo Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Albireo Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2023
Cost of Revenue1.2 M1.2 M
Revenues36.5 M39.4 M
Revenue to Assets 0.15  0.13 
Revenue Per Employee359 K360.5 K

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Albireo Pharma

+0.85KBKB Financial Group Earnings Call TodayPairCorr

Moving against Albireo Pharma

-0.79CVSCVS Health Corp Earnings Call TomorrowPairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to the analysis of Albireo Pharma Correlation against competitors. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
922.9 M
Quarterly Revenue Growth
1.683
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.